Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by RelevantStockon Feb 24, 2021 7:09pm
195 Views
Post# 32654127

RE:RE:RE:RE:WOULD BE NICE

RE:RE:RE:RE:WOULD BE NICEI understand your point Lithlover, but since Tripp has started for the first time to talk about fair valuation in his last presentation (in terms of billions), I started to think that it could be a possibility. Lots of small biotechs need the firepower of major players to launch disruptive products. They are not rolling on flows of money like Stagezero is atm though. Anything goes for me! We would not be bought at discount after 15 years of work and research and patents lol.
LithLover wrote:

Agreed  Been here too many years and put up with too much to be bought out early .  I want to see dollars and nasdaq before those conversations happen and hopefully by then Tripp has marketed the heck out of this company   



Str8Shuter wrote: Personally, as a long-term shareholder I would NOT want any buyout deal until SZLS has grown by leaps and bounds organically with Aristotle becoming a recognized name in the liquid biopsy space.  Otherwise, retail investors will likely only get squeezed out of the picture way too early.  Hopefully a buyout doesn't happen until the SP has reached tens of dollars trading on NASDAQ.  But that's just me.    :-)

GLTA!
 

RelevantStock wrote:
capebretongirl wrote: To see a strong close followed by a Halt at 0940 tomorrow a.m. with news to follow...... that would be momentum.


or crazier scenario: halt + buyout news haha. Why not?!.. If I wanted to buy Stagezero, I'd probably do it before the Aristotle launch, that I'd want to market in my own way.






<< Previous
Bullboard Posts
Next >>